Pathogenic role of scavenger receptor CD36, metabolic syndrome and Diabetes

Metabolic Syndrome and Related Disorders

Volumn 9, Issue 4, 2011, Pages 239-245

  Kennedy, David J ^a   Kashyap, Sangeeta R ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD36 ANTIGEN; INSULIN; SCAVENGER RECEPTOR B; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR;

ATHEROGENESIS; CELL ACTIVATION; DIABETES MELLITUS; ENZYME ACTIVATION; FATTY ACID TRANSPORT; INFLAMMATION; INSULIN RESISTANCE; MACROPHAGE; METABOLIC SYNDROME X; MONOCYTE; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ADIPOSE TISSUE; ANIMALS; ANTIGENS, CD36; ATHEROSCLEROSIS; DIABETES MELLITUS; HUMANS; INFLAMMATION; INSULIN RESISTANCE; MACROPHAGES; METABOLIC SYNDROME X; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION;

EID: 79960825294     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2011.0003     Document Type: Review

References (67)

1. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996;271:518-520.
2. Sun M, Finnemann SC, Febbraio M, Shan L, Annangudi SP, Podrez EA, Hoppe G, Darrow R, Organisciak DT, Salomon RG, Silverstein RL, Hazen SL. Light-induced oxidation of photoreceptor outer segment phospholipids generates ligands for CD36-mediated phagocytosis by retinal pigment epithelium: a potential mechanism for modulating outer segment phagocytosis under oxidant stress conditions. J Biol Chem 2006;281:4222-4230. (Pubitemid 43847851)
3. Elomaa O, Kangas M, Sahlberg C, Tuukkanen J, Sormunen R, Liakka A, Thesleff I, Kraal G, Tryggvason K. Cloning of a novel bacteria-binding receptor structurally related to scavenger receptors and expressed in a subset of macrophages. Cell 1995;80:603-609.
4. Feng J, Han J, Pearce SF, Silverstein RL, Gotto AM, Jr., Hajjar DP, Nicholson AC. Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPAR-gamma. J Lipid Res 2000;41:688-696.
5. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005;115:1111-1119. (Pubitemid 40629025)
6. Schenk S, Horowitz JF. Coimmunoprecipitation of FAT/CD36 and CPT I in skeletal muscle increases proportionally with fat oxidation after endurance exercise training. Am J Physiol Endocrinol Metab 2006;291:E254-E260. (Pubitemid 44035283)
7. Podrez EA, Byzova TV, Febbraio M, Salomon RG, Ma Y, Valiyaveettil M, Poliakov E, Sun M, Finton PJ, Curtis BR, Chen J, Zhang R, Silverstein RL, Hazen SL. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med 2007;13:1086-1095. (Pubitemid 47517507)
8. Febbraio M, Podrez EA, Smith JD, Hajjar DP, Hazen SL, Hoff HF, Sharma K, Silverstein RL. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 2000;105:1049-1056. (Pubitemid 30217689)
9. Rahaman SO, Lennon DJ, Febbraio M, Podrez EA, Hazen SL, Silverstein RL. A CD36-dependent signaling cascade is necessary for macrophage foam cell formation. Cell Metab 2006;4:211-221. (Pubitemid 44283954)
10. Cho S, Park EM, Febbraio M, Anrather J, Park L, Racchumi G, Silverstein RL, Iadecola C. The class B scavenger receptor CD36 mediates free radical production and tissue injury in cerebral ischemia. J Neurosci 2005;25:2504-2512. (Pubitemid 40365160)
11. Simantov R, Febbraio M, Silverstein RL. The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein. Matrix Biol 2005;24:27-34. (Pubitemid 40320896)
12. Glintborg D, Hojlund K, Andersen M, Henriksen JE, Beck- Nielsen H, Handberg A. Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment. Diabetes Care 2008;31:328-334. (Pubitemid 351213346)
13. Handberg A, Levin K, Hojlund K, Beck-Nielsen H. Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma: A novel marker of insulin resistance. Circulation 2006;114:1169-1176. (Pubitemid 44386481)
14. Sampson MJ, Davies IR, Braschi S, Ivory K, Hughes DA. Increased expression of a scavenger receptor (CD36) in monocytes from subjects with type 2 diabetes. Atherosclerosis 2003;167:129-134. (Pubitemid 36255644)
15. Koonen DP, Glatz JF, Bonen A, Luiken JJ. Long-chain fatty acid uptake and FAT/CD36 translocation in heart and skeletal muscle. Biochim Biophys Acta 2005;1736:163-180. (Pubitemid 41423701)
16. Huang H, Campbell SC, Bedford DF, Nelius T, Veliceasa D, Shroff EH, Henkin JH, Schneider A, Bouck N, Volpert OV. Peroxisome proliferator-activated receptor gamma ligands improve the antitumor efficacy of thrombospondin peptide ABT510. Mol Cancer Res 2004;2:541-550. (Pubitemid 39403382)
17. Moore KJ, El Khoury J, Medeiros LA, Terada K, Geula C, Luster AD, Freeman MW. A CD36-initiated signaling cascade mediates inflammatory effects of beta-amyloid. J Biol Chem 2002;277:47373-47379. (Pubitemid 36163374)
18. Febbraio M, Abumrad NA, Hajjar DP, Sharma K, Cheng W, Pearce SF, Silverstein RL. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J Biol Chem 1999;274:19055-19062.
19. Kunjathoor VV, Febbraio M, Podrez EA, Moore KJ, Andersson L, Koehn S, Rhee JS, Silverstein R, Hoff HF, Freeman MW. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem 2002;277:49982-49988. (Pubitemid 36014449)
20. Holvoet P, Lee DH, Steffes M, Gross M, Jacobs DR Jr. Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome. JAMA 2008;299:2287-2293. (Pubitemid 351724395)
21. Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol 2009;6:399-409.
22. Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, Pratipanawatr T, DeFronzo RA, Kahn CR, Mandarino LJ. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000;105:311-320. (Pubitemid 30094451)
23. Marleau S, Harb D, Bujold K, Avallone R, Iken K, Wang Y, Demers A, Sirois MG, Febbraio M, Silverstein RL, Tremblay A, Ong H. EP 80317, a ligand of the CD36 scavenger receptor, protects apolipoprotein E-deficient mice from developing atherosclerotic lesions. FASEB J 2005;19:1869-1871. (Pubitemid 41598778)
24. Febbraio M, Guy E, Silverstein RL. Stem cell transplantation reveals that absence of macrophage CD36 is protective against atherosclerosis. Arterioscler Thromb Vasc Biol 2004;24:2333-2338. (Pubitemid 39658038)
25. Kennedy DJ, Kuchibhotla S, Westfall KM, Silverstein RL, Morton RE, Febbraio M. A CD36-dependent pathway enhances macrophage and adipose inflammation and impairs insulin signaling. Cardiovasc Res 2011;89:604-613.
26. Kuniyasu A, Hayashi S, Nakayama H. Adipocytes recognize and degrade oxidized low density lipoprotein through CD36. Biochem Biophys Res Commun 2002;295:319-323. (Pubitemid 34785836)
27. Scazzocchio B, Vari R, D'Archivio M, Santangelo C, Filesi C, Giovannini C, Masella R. Oxidized LDL impair adipocyte response to insulin by activating serine/threonine kinases. J Lipid Res 2009;50:832-845.
28. Gordon S. Pattern recognition receptors: Doubling up for the innate immune response. Cell 2002;111:927-930. (Pubitemid 36044685)
29. Krieger M. The other side of scavenger receptors: pattern recognition for host defense. Curr Opin Lipidol 1997;8:275-280. (Pubitemid 27462434)
30. Hoebe K, Georgel P, Rutschmann S, Du X, Mudd S, Crozat K, Sovath S, Shamel L, Hartung T, Zahringer U, Beutler B. CD36 is a sensor of diacylglycerides. Nature 2005;433:523-527. (Pubitemid 40204309)
31. Stewart CR, Stuart LM, Wilkinson K, van Gils JM, Deng J, Halle A, Rayner KJ, Boyer L, Zhong R, Frazier WA, Lacy- Hulbert A, El Khoury J, Golenbock DT, Moore KJ. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol 2010;11:155-161.
32. Triantafilou M, Gamper FG, Haston RM, Mouratis MA, Morath S, Hartung T, Triantafilou K. Membrane sorting of toll-like receptor (TLR)-2/6 and TLR2/1 heterodimers at the cell surface determines heterotypic associations with CD36 and intracellular targeting. J Biol Chem 2006;281:31002-31011. (Pubitemid 44582155)
33. Stuart LM, Deng J, Silver JM, Takahashi K, Tseng AA, Hennessy EJ, Ezekowitz RAB, Moore KJ. Response to Staphylococcus aureus requires CD36-mediated phagocytosis triggered by the COOH-terminal cytoplasmic domain. J Cell Biol 2005;170:477-485. (Pubitemid 41126946)
34. Bamberger ME, Harris ME, McDonald DR, Husemann J, Landreth GE. A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J Neurosci 2003;23:2665-2674. (Pubitemid 36418601)
35. Erdman LK, Cosio G, Helmers AJ, Gowda DC, Grinstein S, Kain KC. CD36 and TLR interactions in inflammation and phagocytosis: Implications for malaria. J Immunol 2009;183: 6452-6459.
36. Morino K, Petersen KF, Shulman GI. Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes 2006;55(Suppl 2): S9-S15. (Pubitemid 44927027)
37. Huang MM, Bolen JB, Barnwell JW, Shattil SJ, Brugge JS. Membrane glycoprotein IV (CD36) is physically associated with the Fyn, Lyn, and Yes protein-tyrosine kinases in human platelets. Proc Natl Acad Sci USA 1991;88:7844-7848. (Pubitemid 21915251)
38. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathwa ys mediated by ERK, JNK, and p38 protein kinases. Science 2002;298:1911-1912. (Pubitemid 35425238)
39. Miki S, Horikawa K, Nishizumi H, Suemura M, Sato B, Yamamoto M, Takatsu K, Yamamoto T, Miki Y. Reduction of atherosclerosis despite hypercholesterolemia in lyn-deficient mice fed a high-fat diet. Genes Cells 2001;6:37-42. (Pubitemid 32156752)
40. Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest 1993;92:141-146. (Pubitemid 23208989)
41. Carantoni M, Abbasi F, Warmerdam F, Klebanov M, Wang PW, Chen YDI, Azhar S, Reaven GM. Relationship between insulin resistance and partially oxidized LDL particles in healthy, nondiabetic volunteers. Arterioscler Thromb Vasc Biol 1998;18:762-767. (Pubitemid 28267656)
42. Adachi T, Pimentel DR, Heibeck T, Hou X, Lee YJ, Jiang B, Ido Y, Cohen RA. S-glutathiolation of Ras mediates redoxsensitive signaling by angiotensin II in vascular smooth muscle cells. J Biol Chem 2004;279:29857-29862. (Pubitemid 38915870)
43. Clavreul N, Adachi T, Pimental DR, Ido Y, Schoneich C, Cohen RA. S-glutathiolation by peroxynitrite of p21ras at cysteine-118 mediates its direct activation and downstream signaling in endothelial cells. FASEB J 2006;20:518-520. (Pubitemid 46671235)
44. Clavreul N, Bachschmid MM, Hou X, Shi C, Idrizovic A, Ido Y, Pimental D, Cohen RA. S-glutathiolation of p21ras by peroxynitrite mediates endothelial insulin resistance caused by oxidized low-density lipoprotein. Arterioscler Thromb Vasc Biol 2006;26:2454-2461. (Pubitemid 44607465)
45. Solinas G, Vilcu C, Neels JG, Bandyopadhyay GK, Luo JL, Naugler W, Grivennikov S, Wynshaw-Boris A, Scadeng M, Olefsky JM, Karin M. JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. Cell Metab 2007;6:386-397. (Pubitemid 350012000)
46. Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R, Miyachi H, Maeda S, Egashira K, Kasuga M. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006;116:1494-1505.
47. Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, Vaddi K, Charo I, Leibel RL, Ferrante AW Jr. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 2006;116:115-124. (Pubitemid 43121796)
48. Sabio G, Das M, Mora A, Zhang Z, Jun JY, Ko HJ, Barrett T, Kim JK, Davis RJ. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 2008;322:1539-1543.
49. Vallerie SN, Furuhashi M, Fucho R, Hotamisligil GS. A predominant role for parenchymal c-Jun amino terminal kinase (JNK) in the regulation of systemic insulin sensitivity. PLoS One 2008;3:e3151.
50. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS. A central role for JNK in obesity and insulin resistance. Nature 2002;420:333-336. (Pubitemid 35398190)
51. Furuhashi M, Ura N, Nakata T, Tanaka T, Shimamoto K. Genotype in human CD36 deficiency and diabetes mellitus. Diabet Med 2004;21:952-953. (Pubitemid 39037016)
52. Kuwasako T, Hirano K, Sakai N, Ishigami M, Hiraoka H, Yakub MJ, Yamauchi-Takihara K, Yamashita S, Matsuzawa Y. Lipoprotein Abnormalities in Human Genetic CD36 Deficiency Associated With Insulin Resistance and Abnormal Fatty Acid Metabolism. Diabetes Care 2003;26: 1647-1648. (Pubitemid 36929222)
53. Yamashita S, Hirano KI, Kuwasako T, Janabi M, Toyama Y, Ishigami M, Sakai N. Physiological and pathological roles of a multi-ligand receptor CD36 in atherogenesis; insights from CD36-deficient patients. Mol Cell Biochem 2007;299:19-22. (Pubitemid 46767534)
54. Corpeleijn E, van der Kallen CJ, Kruijshoop M, Magagnin MG, de Bruin TW, Feskens EJ, Saris WHM, Blaak EE. Direct association of a promoter polymorphism in the CD36/FAT fatty acid transporter gene with Type 2 diabetes mellitus and insulin resistance. Diabet Med 2006;23:907-911. (Pubitemid 44141081)
55. Lepretre F, Vasseur F, Vaxillaire M, Scherer PE, Ali S, Linton K, Aitman T, Froguel P. A CD36 nonsense mutation associated with insulin resistance and familial type 2 diabetes. Hum Mutat 2004;24:104.
56. Kajihara S, Hisatomi A, Ogawa Y, Yasutake T, Yoshimura T, Hara T, Mizuta T, Ozaki I, Iwamoto N, Yamamoto K. Association of the Pro90Ser CD36 mutation with elevated free fatty acid concentrations but not with insulin resistance syndrome in Japanese. Clin Chim Acta 2001;314:125-130. (Pubitemid 33079191)
57. Yanai H, Chiba H, Morimoto M, Jamieson GA, Matsuno K. Type I CD36 deficiency in humans is not associated with insulin resistance syndrome. Thromb Haemost 2000;83:786. (Pubitemid 30248531)
58. Pravenec M, Landa V, Zidek V, Musilova A, Kazdova L, Qi N, Wang J, St Lezin E, Kurtz TW. Transgenic expression of CD36 in the spontaneously hypertensive rat is associated with amelioration of metabolic disturbances but has no effect on hypertension. Physiol Res 2003;52:681-688. (Pubitemid 38090097)
59. Bonen A, Tandon NN, Glatz JF, Luiken JJ, Heigenhauser GJ. The fatty acid transporter FAT/CD36 is upregulated in subcutaneous and visceral adipose tissues in human obesity and type 2 diabetes. Int J Obes (Lond) 2006;30:877-883. (Pubitemid 43801185)
60. Goudriaan JR, Dahlmans VE, Teusink B, Ouwens DM, Febbraio M, Maassen JA, Romijn JA, Havekes LM, Voshol PJ. CD36 deficiency increases insulin sensitivity in muscle, but induces insulin resistance in the liver in mice. J Lipid Res 2003;44:2270-2277. (Pubitemid 38082485)
61. Liang CP, Han S, Okamoto H, Carnemolla R, Tabas I, Accili D, Tall AR. Increased CD36 protein as a response to defective insulin signaling in macrophages. J Clin Invest 2004;113:764-773. (Pubitemid 38544170)
62. Zhang HM, Zhang XL, Zhou X, Li D, Gu JG, Wu JJ. [Mechanism linking atherosclerosis and type 2 diabetes: increased expression of scavenger receptor CD36 in monocytes.]. Chin Med J (Engl) 2005;118:1717-1722. (Pubitemid 41631681)
63. Alkhatatbeh MJ, Mhaidat NM, Enjeti AK, Lincz LF, Thorne RF. The putative diabetic plasma marker, soluble CD36, is non-cleaved, non-soluble and entirely associated with microparticles. J Thromb Haemost 2011:doi: 10.1111/j.1538-7836. 2011.04220.x.
64. Ghosh A, Li W, Febbraio M, Espinola RG, McCrae KR, Cockrell E, Silverstein RL. Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice. J Clin Invest 2008;118: 1934-1943. (Pubitemid 351632395)
65. Susztak K, Ciccone E, McCue P, Sharma K, Bottinger EP. Multiple metabolic hits converge on CD36 as novel mediator of tubular epithelial apoptosis in diabetic nephropathy. PLoS Med 2005;2:e45.
66. Eibl N, Krugluger W, Streit G, Schrattbauer K, Hopmeier P, Schernthaner G. Improved metabolic control decreases platelet activation markers in patients with type-2 diabetes. Eur J Clin Invest 2004;34:205-209. (Pubitemid 38406635)
67. Kashyap SR, Ioachimescu AG, Gornik HL, Gopan T, Davidson MB, Makdissi A, Major J, Febbraio M, Silverstein RL. [Lipid-induced insulin resistance is associated with increased monocyte expression of scavenger receptor CD36 and internalization of oxidized LDL. Obesity 2009;17:2142-2148.